{
  "id": 2383498,
  "title": "The cost of waiting: what licensing a biotech asset early really saves you",
  "url": "https://urgent.news/2026/08/21/the-cost-of-waiting-what-licensing-a-biotech-asset-early-really-saves",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-21T13:00:00.000Z",
  "source": {
    "name": "Labiotech",
    "slug": "labiotech",
    "url": "https://www.labiotech.eu/opinion/cost-of-waiting-licensing-biotech-asset-early/"
  },
  "original_language": "en",
  "account": null,
  "summary": "In recent years, biopharma has paid significantly different prices for the same underlying technology. In March 2025, AstraZeneca agreed to pay EsoBiotec, an in vivo CAR-T platform with early single-patient data, $425 million upfront and up to $575 million more in milestones. In August 2025, Gilead’s Kite paid $350 million for Interius BioTherapeutics, another in vivo CAR-T platform, also…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}